Indeed, only 42% of devices explicitly for bridging and 6%
of devices for “bridge to candidacy” were replaced by heart
transplants at the time of the last annual report of
INTERMACS.14 Thus the majority of VADs are for lifetime
support; although initially implanted for life prolongation,
they will eventually become end-of life VADs.